Literature DB >> 17559064

Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor.

Andreas Axén1, Hanna Andersson, Gunnar Lindeberg, Harriet Rönnholm, Jarkko Kortesmaa, Heidi Demaegdt, Georges Vauquelin, Anders Karlén, Mathias Hallberg.   

Abstract

Angiotensin IV analogs encompassing aromatic scaffolds replacing parts of the backbone of angiotensin IV have been synthesized and evaluated in biological assays. Several of the ligands displayed high affinities to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor. Displacement of the C-terminal of angiotensin IV with an o-substituted aryl acetic acid derivative delivered the ligand 4, which exhibited the highest binding affinity (K(i) = 1.9 nM). The high affinity of this ligand provides support to the hypothesis that angiotensin IV adopts a gamma-turn in the C-terminal of its bioactive conformation. Ligand (4) inhibits both human IRAP and aminopeptidase N-activity and induces proliferation of adult neural stem cells at low concentrations. Furthermore, ligand 4 is degraded considerably more slowly in membrane preparations than angiotensin IV. Hence, it might constitute a suitable research tool for biological studies of the (IRAP)/AT(4) receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559064     DOI: 10.1002/psc.859

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  8 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers.

Authors:  Anthony L Albiston; Shanti Diwakarla; Ruani N Fernando; Simon J Mountford; Holly R Yeatman; Broden Morgan; Vi Pham; Jessica K Holien; Michael W Parker; Philip E Thompson; Siew Yeen Chai
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

4.  Macrocyclic peptidomimetics as inhibitors of insulin-regulated aminopeptidase (IRAP).

Authors:  Nicholas Barlow; Sudarsana Reddy Vanga; Jonas Sävmarker; Anja Sandström; Peta Burns; Anders Hallberg; Johan Åqvist; Hugo Gutiérrez-de-Terán; Mathias Hallberg; Mats Larhed; Siew Yeen Chai; Philip E Thompson
Journal:  RSC Med Chem       Date:  2020-01-08

5.  Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides.

Authors:  Sudarsana Reddy Vanga; Jonas Sävmarker; Leelee Ng; Mats Larhed; Mathias Hallberg; Johan Åqvist; Anders Hallberg; Siew Yeen Chai; Hugo Gutiérrez-de-Terán
Journal:  ACS Omega       Date:  2018-04-25

6.  Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.

Authors:  Hanna Andersson; Mathias Hallberg
Journal:  Int J Hypertens       Date:  2012-12-04       Impact factor: 2.420

7.  Synthesis, Evaluation and Proposed Binding Pose of Substituted Spiro-Oxindole Dihydroquinazolinones as IRAP Inhibitors.

Authors:  Karin Engen; Sudarsana Reddy Vanga; Thomas Lundbäck; Faith Agalo; Vivek Konda; Annika Jenmalm Jensen; Johan Åqvist; Hugo Gutiérrez-de-Terán; Mathias Hallberg; Mats Larhed; Ulrika Rosenström
Journal:  ChemistryOpen       Date:  2020-03-02       Impact factor: 2.911

Review 8.  From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase.

Authors:  Mathias Hallberg; Mats Larhed
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.